Enzon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net income was USD 0.701 million compared to net loss of USD 0.519 million a year ago. Basic loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.01 compared to USD 0.03 a year ago.